General:

• Broad prevention of over-production of inflammatory Th1 cytokines and not just one cytokine, e.g., TNF (TNF and IFN-γ act in strong synergy for inflammation)
• High potential efficacy and safety due to mechanism specificity

In acute diseases:

• The only technology shown to prevent the overwhelming, harmful effects of superantigens on the immune system caused by excessive Th1-cytokine storm
• Broad activity in sepsis: peptides reduce Th1 cytokines response whether challenge is by superantigens, Gram-positive or Gram-negative bacteria, a broader action than of other therapeutics to date

In chronic diseases:

• Short peptides are non-immunogenic (whereas biologics are immunogenic), central for treatment of autoimmune diseases
• Th2 cytokine response remains unaffected, which flags immunocompetence
• Basal Th1 response remains intact, thus, normal immune responses against opportunistic infections / cancer, are not compromised (limitation of current anti-TNFs)
• Stronger competitive position due to competitive pricing, enabled by lower production costs of short peptide vs. recombinant biologics

Leadership:

• A leading team Drs. Raymond Kaempfer and Gila Arad, Atox Bio Scientific Founders, are recognized worldwide as leaders in the field of superantigens